2021
DOI: 10.3389/fphar.2021.652979
|View full text |Cite
|
Sign up to set email alerts
|

Risk of Fracture During Androgen Deprivation Therapy Among Patients With Prostate Cancer: A Systematic Review and Meta-Analysis of Cohort Studies

Abstract: Background: Androgen deprivation therapy (ADT) suppresses the production of androgen, and ADT is broadly used for intermediate or higher risk disease including advanced and metastatic cancer. ADT is associated with numerous adverse effects derived from the pharmacological properties. Previous meta-analysis on fracture risk among ADT users possessed limited data without further subgroup analysis. Risk estimation of updated real-world evidence on ADT-related fracture remains unknown.Objectives: To assess the ris… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 11 publications
(4 citation statements)
references
References 39 publications
0
4
0
Order By: Relevance
“…In one meta-analysis, the risk of fracture in patients with PCa was 39% higher in those receiving ADT. 22 BMD reduction occurs rapidly after ADT initiation, within 6 to 12 months, and in a dose-dependent manner. Furthermore, the risk for fracture persists beyond ADT discontinuation.…”
Section: Discussionmentioning
confidence: 99%
“…In one meta-analysis, the risk of fracture in patients with PCa was 39% higher in those receiving ADT. 22 BMD reduction occurs rapidly after ADT initiation, within 6 to 12 months, and in a dose-dependent manner. Furthermore, the risk for fracture persists beyond ADT discontinuation.…”
Section: Discussionmentioning
confidence: 99%
“…ADT was also associated with increased fracture risk (OR, 1.39; 95% CI, 1.26–1.52) and fracture requiring hospitalization (OR, 1.55; 95% CI, 1.29–1.88) among patients with prostate cancer, including those with different disease conditions, treatment regimens, dose levels and fracture sites (Wu et al, 2021).…”
Section: Androgensmentioning
confidence: 99%
“…The initiation of ADT results in rapid and profound hypogonadism, resulting in significant bone and muscle loss, increasing the risk for osteoporosis (OP), falls, and fractures [ 14 , 15 , 16 ]. Men receiving ADT have been shown to have a 5- to 10-fold increased loss of bone mass [ 14 , 17 , 18 ], and the risk of fracture has been reported up to 20% by 5 years of treatment [ 19 , 20 , 21 , 22 ], an at least 50% greater risk of fractures than in healthy controls or men with PCa who are not on ADT [ 20 , 21 , 22 , 23 ]. In a large SEER database study, 58% of men at high risk and 38% of men at low risk for fracture at baseline developed at least one fracture after ADT [ 24 ].…”
Section: Introductionmentioning
confidence: 99%